184 related articles for article (PubMed ID: 24420527)
21. Contemporary radical cystectomy outcomes in patients with invasive bladder cancer: a population-based study.
Patel MI; Bang A; Gillatt D; Smith DP
BJU Int; 2015 Oct; 116 Suppl 3():18-25. PubMed ID: 26334934
[TBL] [Abstract][Full Text] [Related]
22. Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer.
Boorjian SA; Kim SP; Tollefson MK; Carrasco A; Cheville JC; Thompson RH; Thapa P; Frank I
J Urol; 2013 Jul; 190(1):55-60. PubMed ID: 23313198
[TBL] [Abstract][Full Text] [Related]
23. Use of radical cystectomy for patients with invasive bladder cancer.
Gore JL; Litwin MS; Lai J; Yano EM; Madison R; Setodji C; Adams JL; Saigal CS;
J Natl Cancer Inst; 2010 Jun; 102(11):802-11. PubMed ID: 20400716
[TBL] [Abstract][Full Text] [Related]
24. Bladder function preservation with brachytherapy, external beam radiation therapy, and limited surgery in bladder cancer patients: Long-term results [corrected].
Aluwini S; van Rooij PH; Kirkels WJ; Boormans JL; Kolkman-Deurloo IK; Wijnmaalen A
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):611-7. PubMed ID: 24411629
[TBL] [Abstract][Full Text] [Related]
25. Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy.
Koie T; Ohyama C; Yamamoto H; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Kitayam M; Hirota K
Urol Oncol; 2014 Aug; 32(6):820-5. PubMed ID: 24951323
[TBL] [Abstract][Full Text] [Related]
26. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy.
Lotan Y; Gupta A; Shariat SF; Palapattu GS; Vazina A; Karakiewicz PI; Bastian PJ; Rogers CG; Amiel G; Perotte P; Schoenberg MP; Lerner SP; Sagalowsky AI
J Clin Oncol; 2005 Sep; 23(27):6533-9. PubMed ID: 16116151
[TBL] [Abstract][Full Text] [Related]
27. Sarcopenia as a comorbidity-independent predictor of survival following radical cystectomy for bladder cancer.
Mayr R; Gierth M; Zeman F; Reiffen M; Seeger P; Wezel F; Pycha A; Comploj E; Bonatti M; Ritter M; van Rhijn BWG; Burger M; Bolenz C; Fritsche HM; Martini T
J Cachexia Sarcopenia Muscle; 2018 Jun; 9(3):505-513. PubMed ID: 29479839
[TBL] [Abstract][Full Text] [Related]
28. Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a.
May M; Bastian PJ; Brookman-May S; Fritsche HM; Tilki D; Otto W; Bolenz C; Gilfrich C; Trojan L; Herrmann E; Moritz R; Tiemann A; Müller SC; Ellinger J; Buchner A; Stief CG; Wieland WF; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Nuhn P; Burger M
Urol Oncol; 2013 Oct; 31(7):1141-7. PubMed ID: 22056404
[TBL] [Abstract][Full Text] [Related]
29. Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer.
Margel D; Tal R; Baniel J
J Urol; 2007 Dec; 178(6):2297-300; discussion 2300-1. PubMed ID: 17936837
[TBL] [Abstract][Full Text] [Related]
30. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center.
Kotwal S; Choudhury A; Johnston C; Paul AB; Whelan P; Kiltie AE
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):456-63. PubMed ID: 17904301
[TBL] [Abstract][Full Text] [Related]
31. Multiple adverse histological features increase the odds of under staging T1 bladder cancer.
Weizer AZ; Wasco MJ; Wang R; Daignault S; Lee CT; Shah RB
J Urol; 2009 Jul; 182(1):59-65; discussion 65. PubMed ID: 19447443
[TBL] [Abstract][Full Text] [Related]
32. Treatment delay and prognosis in invasive bladder cancer.
Liedberg F; Anderson H; Månsson W
J Urol; 2005 Nov; 174(5):1777-81; discussion 1781. PubMed ID: 16217282
[TBL] [Abstract][Full Text] [Related]
33. A population based assessment of perioperative mortality after cystectomy for bladder cancer.
Isbarn H; Jeldres C; Zini L; Perrotte P; Baillargeon-Gagne S; Capitanio U; Shariat SF; Arjane P; Saad F; McCormack M; Valiquette L; Peloquin F; Duclos A; Montorsi F; Graefen M; Karakiewicz PI
J Urol; 2009 Jul; 182(1):70-7. PubMed ID: 19447427
[TBL] [Abstract][Full Text] [Related]
34. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.
Gray PJ; Fedewa SA; Shipley WU; Efstathiou JA; Lin CC; Zietman AL; Virgo KS
Eur Urol; 2013 May; 63(5):823-9. PubMed ID: 23200811
[TBL] [Abstract][Full Text] [Related]
35. The effect of socioeconomic status on staging and treatment decisions in esophageal cancer.
Bus P; Aarts MJ; Lemmens VE; van Oijen MG; Creemers GJ; Nieuwenhuijzen GA; van Baal JW; Siersema PD
J Clin Gastroenterol; 2012; 46(10):833-9. PubMed ID: 22460163
[TBL] [Abstract][Full Text] [Related]
36. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
[TBL] [Abstract][Full Text] [Related]
37. Comparison of radical cystectomy with conservative treatment in geriatric (≥80) patients with muscle-invasive bladder cancer.
Martini T; Mayr R; Wehrberger C; Dechet C; Lodde M; Palermo S; Trenti E; Comploj E; Pycha A; Madersbacher S
Int Braz J Urol; 2013; 39(5):622-30. PubMed ID: 24267105
[TBL] [Abstract][Full Text] [Related]
38. Oncological outcome of primary versus secondary muscle-invasive bladder cancer is comparable after radical cystectomy.
Aziz A; Gierth M; Fritsche HM; May M; Otto W; Denzinger S; Wieland WF; Merseburger A; Riedmiller H; Kocot A; Burger M
Urol Int; 2013; 91(1):97-102. PubMed ID: 23751372
[TBL] [Abstract][Full Text] [Related]
39. Association of steroid and xenobiotic receptor (SXR) and multidrug resistance 1 (MDR1) gene expression with survival among patients with invasive bladder carcinoma.
Rioja J; Bandrés E; Rosell Costa D; Rincón A; López I; Zudaire Bergera JJ; García Foncillas J; Gil MJ; Panizo A; Plaza L; Rioja LA; Berián Polo JM
BJU Int; 2011 Jun; 107(11):1833-8. PubMed ID: 20840328
[TBL] [Abstract][Full Text] [Related]
40. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
